100
Participants
Start Date
November 12, 2003
Primary Completion Date
July 28, 2005
Study Completion Date
July 28, 2005
ALX-0600
teduglutide
placebo
placebo solution injected subcutaneously
teduglutide 0.05
0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
teduglutide 0.2 mg
0.2 mg/kg/d subcutaneously injected into thigh or abdomen
Teduglutide 0.05 dose
0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
teduglutide 0.1 mg dose
0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Asher Kornbluth, MD, PC, New York
Long Island Clinical Research Associates, Great Neck
Allegheny General Hospital-Allegheny Ctr for Digestive Diseases, Pittsburgh
Rx Trials, Washington D.C.
McGuire DVAMC, Richmond
Emory University School of Medicine, Atlanta
Pinnacle Trials, Atlanta
Venture Research, North Miami Beach
Clinical Trials Management of Boca Raton, Boca Raton
Clinical Research of West Florida, Clearwater
Visions Clinical Research - Sarasota, Sarasota
University of Louisville, Louisville
Cleveland Clinic Foundation, Cleveland
Dean Foundation Research Center, Madison
Northwestern University School of Medicine, Chicago
University of Chicago, Chicago
Methodist Hospital/Baylor University, Houston
Rocky Mountain Gastroenterology, Lakewood
University of Utah, Salt Lake City
Advanced Clinical Therapeutics, Tucson
Saint Joseph's Health System, Atlanta
Vancouver General Hospital, Vancouver
Odyssey Research, Victoria
Health Sciences Center, Winnipeg
Queen Elizabeth II Health Sciences, Halifax
Life Screening Centres, Toronto
Lead Sponsor
Shire
INDUSTRY